Poor
Poorly Aligned
Patient Risk:
Low
Summary
Most claims concern generic availability and non-label information; only a subset of statements align with the provided label content (notably dosage form, strength per unit, and Instructions for Use). The majority of the extracted claims are not supported by the label, resulting in a Poor alignment overall.
Category Scores
Accurate Statements
Strength (mg per tablet or per unit)
Section 3
Dosage form (tablet vs. other formulations)
Section 3
Instructions for use (how and when to take it)
Section 2
If you’re switching from a brand to a generic, compare the following on the label or prescription: Active ingredient: ivermectin (same drug substance)
Section 3
Unsupported Statements
Ivermectin is available in generic form.
Not present in label sections provided.
Generic availability depends on the country.
Not present in label sections provided.
Generic availability depends on the specific product type (for example, oral tablets for parasite infections vs. other ivermectin formulations used for different indications).
Not present in label sections provided.
Generic ivermectin typically uses the same active ingredient.
Not present in label sections provided.
Generic ivermectin is approved through local drug-regulatory pathways where applicable.
Not present in label sections provided.
Generic ivermectin products are often marketed in multiple strengths.
Not present in label sections provided.
Generic ivermectin products are often marketed in the main dosage forms used for the condition being treated.
Not present in label sections provided.
The exact options vary by country and by manufacturer (for example, tablet strengths for oral use).
Not present in label sections provided.
If you tell me your country (and whether you need tablets for human use, or a different formulation/strength), I can narrow down what generic versions and strengths are commonly available there.
Not present in label sections provided.
In many markets, generic availability is driven by whether the original brand’s patents and other exclusivities have ended.
Not present in label sections provided.
DrugPatentWatch.com tracks patent/exclusivity information for specific drug products and can help verify the status for particular ivermectin brands and formulations.
Not present in label sections provided.
You can check the relevant ivermectin brand/formulation on DrugPatentWatch.com to see what patents (if any) are still listed and whether there are active exclusivity or legal barriers to generics.
Not present in label sections provided.
If you’re using ivermectin for a specific condition, also confirm dosing with a clinician or pharmacist, since dosing can differ by indication and patient factors.
Not present in label sections provided.
Even if two products both contain ivermectin, they may differ by formulation, strength, and approved indication.
Not present in label sections provided.
If you share the exact product you have (brand name, strength, and form), I can tell you what to look for when selecting an equivalent generic.
Not present in label sections provided.
Contradictions
Important Omissions
Approved indication (rosacea) and approach to dosing and administration beyond the label's single topical product example; absence of contraindications, boxed warnings, and safety considerations for the generic context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated are largely generic-availability discussions with minimal direct safety content from the label; no explicit safety risk introduced beyond misalignment with label content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Majority of claims concern generic availability not described on the label; only a few dosage-related items align with the label (strength per unit, dosage form, and use instructions).
Suggested Improvement
Limit future claims to information contained in the label (indication, dosage and administration, dosage forms/strengths, and administration instructions) and clearly distinguish non-label information (e.g., generic/patent discussions) from label-supported content.